Allergan, Inc. headquartered in Irvine, California, is a technology-driven, global health care company providing eye care and specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care pharmaceutical, ophthalmic surgical device, over-the-counter contact lens care, movement disorder, and dermatological markets that deliver value to our customers, satisfy unmet needs and improve patients' lives.
Allergan targets its products and R&D to specific disease areas. These include glaucoma and retinal disease, cataracts, dry eye, psoriasis, acne, photodamage, movement disorders, pain, metabolic disease and various types of cancer. Leading-edge technologies in which the Company has established leadership positions include second-generation alpha2 agonist compounds, receptor-selective retinoids, foldable intraocular lenses (IOLs), injectable neurotoxin and convenient contact lens care products.
Allergan markets products in more than 100 countries. In 1999, sales outside the United States generated approximately 52% of the Company's $1.4 billion worldwide revenue.
Founded in 1950, Allergan became a public company in 1970, merged with SmithKline Beckman in 1980, and was re-established as an independent entity in 1989. Allergan common stock is traded on the New York Stock Exchange under the symbol AGN.
